Genetic and epigenetic evolution as a contributor to WT1-mutant leukemogenesis

Area of Science:

• Hematology
• Cancer Biology
• Molecular Genetics

Background:

• Recurrent somatic mutations, including in the Wilms' tumor 1 (WT1) gene, are identified in acute myeloid leukemia (AML) patients.
• The precise molecular mechanisms linking WT1 mutations to leukemogenesis remain incompletely understood.

Purpose of the Study:

• To investigate the role of WT1 gene dosage in normal (steady-state) and abnormal (pathologic) blood cell formation (hematopoiesis).
• To elucidate the mechanisms by which WT1 loss contributes to the development of AML.

Main Methods:

• Studied the impact of WT1 heterozygous loss on hematopoietic stem cell self-renewal and function over time.
• Analyzed genetic and epigenetic alterations in WT1-haploinsufficient leukemias.
• Investigated the cooperative effect of WT1 depletion with Flt3-ITD mutations in inducing AML.

Main Results:

• WT1 heterozygous loss promoted stem cell self-renewal in an age-dependent manner.
• WT1-haploinsufficient leukemias exhibited progressive genetic and epigenetic changes, necessitating additional events for transformation.
• WT1 depletion cooperated with Flt3-ITD mutations to induce fully penetrant AML.

Conclusions:

• WT1 gene dosage is critical in regulating hematopoietic stem cell function and preventing leukemic transformation.
• Leukemogenesis driven by WT1 loss is a multi-step process requiring cooperating genetic and epigenetic alterations.
• Understanding WT1's role provides insights into AML development and potential therapeutic strategies.